Patrick Jaynes

Patrick Jaynes

Auto-generated profile, based on publicly available information

Patrick Jaynes

Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2024 in Science Advances
Verified
Journal Article
Open access
PHPhuong Mai Hoang
Phuong Mai Hoang
DTDenis Torre
Denis Torre
PJPatrick Jaynes
Patrick Jaynes
JHJessica Ho
Jessica Ho
KMKevin Mohammed
Kevin Mohammed
AJAnand D. Jeyasekharan
Anand D. Jeyasekharan
DNA replication stress (RS) is a widespread phenomenon in carcinogenesis, causing genomic instability and extensive chromatin alterations. DNA damage leads to activation of innate immune signaling, but little is known about transcriptional regulators mediating such signaling upon RS. Using a chemical screen, we identified protein arginine methyltransferase 5 (PRMT5) as a key mediator of RS-dependent induction of interferon-stimulated genes (ISGs). This response is also associated with reactivation of endogenous retroviruses (ERVs). Using quantitative mass spectrometry, we identify proteins with PRMT5-dependent symmetric dimethylarginine (SDMA) modification induced upon RS. Among these, we show that PRMT5 targets and modulates the activity of ZNF326, a zinc finger protein essential for ISG response. Our data demonstrate a role for PRMT5-mediated SDMA in the context of RS-induced transcriptional induction, affecting physiological homeostasis and cancer therapy.

18 April 2023 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
MHMichal Marek Hoppe
Michal Marek Hoppe
PJPatrick Jaynes
Patrick Jaynes
FSFan Shuangyi
Fan Shuangyi
YPYanfen Peng
Yanfen Peng
SSShruti Sridhar
Shruti Sridhar
AJAnand D. Jeyasekharan
Anand D. Jeyasekharan
Cancers often overexpress multiple clinically relevant oncogenes, but it is not known if combinations of oncogenes in cellular subpopulations within a cancer influence clinical outcomes. Using quantitative multispectral imaging of the prognostically relevant oncogenes MYC, BCL2, and BCL6 in diffuse large B-cell lymphoma (DLBCL), we show that the percentage of cells with a unique combination MYC+BCL2+BCL6− (M+2+6−) consistently predicts survival across four independent cohorts (n = 449), an effect not observed with other combinations including M+2+6+. We show that the M+2+6− percentage can be mathematically derived from quantitative measurements of the individual oncogenes and correlates with survival in IHC (n = 316) and gene expression (n = 2,521) datasets. Comparative bulk/single-cell transcriptomic analyses of DLBCL samples and MYC/BCL2/BCL6-transformed primary B cells identify molecular features, including cyclin D2 and PI3K/AKT as candidate regulators of M+2+6− unfavorable biology. Similar analyses evaluating oncogenic combinations at single-cell resolution in other cancers may facilitate an understanding of cancer evolution and therapy resistance. Significance: Using single-cell–resolved multiplexed imaging, we show that selected subpopulations of cells expressing specific combinations of oncogenes influence clinical outcomes in lymphoma. We describe a probabilistic metric for the estimation of cellular oncogenic coexpression from IHC or bulk transcriptomes, with possible implications for prognostication and therapeutic target discovery in cancer. This article is highlighted in the In This Issue feature, p. 1027

4 May 2023
Verified
Other
Open access
MHMichal Marek Hoppe
Michal Marek Hoppe
PJPatrick Jaynes
Patrick Jaynes
FSFan Shuangyi
Fan Shuangyi
YPYanfen Peng
Yanfen Peng
SSShruti Sridhar
Shruti Sridhar
AJAnand D. Jeyasekharan
Anand D. Jeyasekharan
Prognostic significance of subpopulations after R-CHOP therapy. A, Pooled univariate Cox PH model analysis for MYC, BCL2, and BCL6 single oncogene and subpopulations percentage extent as predictors of OS across multiple DLBCL cohorts. Percentage extent was used as a continuous variable in the model at 5% increments (see Survival Analysis) for an unbiased comparison between the variables. Pooled P values were Bonferroni corrected for single oncogenes and subpopulations independently to adjust for multiple testing and are shown for each variable. Hazard ratio (HR) with 95% confidence interval (CI) per 5%-positivity increment is shown (see also Supplementary Table S4). B, Kaplan–Meier OS analysis of dichotomized into M+2+6− high and low groups. Log-rank test, shading denotes 95% CI. An optimal dichotomization cutoff was used for stratification; total patient numbers in each group are shown.

4 May 2023
Verified
Other
Open access
MHMichal Marek Hoppe
Michal Marek Hoppe
PJPatrick Jaynes
Patrick Jaynes
FSFan Shuangyi
Fan Shuangyi
YPYanfen Peng
Yanfen Peng
SSShruti Sridhar
Shruti Sridhar
AJAnand D. Jeyasekharan
Anand D. Jeyasekharan
Validation of prognostic significance of the M+2+6− subpopulation metric in gene-expression datasets. A, Distribution of single oncogene positivity in DLBCL cohorts as assessed by mfIHC (see Supplementary Fig. S9A and S9B). B, Impact of subpopulation metrics in GEP datasets on OS. Pooled univariate Cox PH model analysis; metric was used as a continuous variable in the model at 5% increments. HR per 5% increment with 95% CI is shown; CI are proportional on both tails but are capped at the graph's edges. Pooled P values were Bonferroni corrected to adjust for multiple testing and are shown for each subpopulation. C, Kaplan–Meier OS analysis of GEP cohorts stratified uniformly across absolute 15% M+2+6− metric into -high and -low groups. Log-rank test, shading denotes 95% CI. Total patient numbers in each group are shown. CMMC, Chi-Mei Medical Center.

18 April 2023
Verified
Other
Open access
MHMichal Marek Hoppe
Michal Marek Hoppe
PJPatrick Jaynes
Patrick Jaynes
FSFan Shuangyi
Fan Shuangyi
YPYanfen Peng
Yanfen Peng
SSShruti Sridhar
Shruti Sridhar
AJAnand D. Jeyasekharan
Anand D. Jeyasekharan
Supplementary table 1. Per-patient mfIHC MYC, BCL2 and BCL6 single oncogene and subpopulation scores for normal tonsil tissue and reactive lymph node tissue. Supplementary table 2. Per-patient mfIHC MYC, BCL2 and BCL6 single oncogene and subpopulation scores for DLBCL tissue (NUH, CMMC, SGH, MDA, BCA and UP). Supplementary table 6. Inferred percentage extents of MYC, BCL2, BCL6 and sub-population metrics in GEP cohorts. Supplementary table 11. Correlation of M+2+6- metric with gene expression in GEP cohorts. Supplementary table 12. Differential gene expression analysis of primary germinal center (GC) B-cells with M+2+ and M+2+6+ overexpression. Supplementary table 13. Differentially expressed genes between M+2+6- and all other malignant cells in scRNA-seq samples of DLBCL. Dichotomized non-parametric comparison, Wilcoxon rank sum test. Supplementary table 14. Analysis of positive enrichment of Wikipathways terms between M+2+6- and all other malignant cells in scRNA-seq samples of DLBCL by gprofiler2.

4 May 2023
Verified
Other
Open access
MHMichal Marek Hoppe
Michal Marek Hoppe
PJPatrick Jaynes
Patrick Jaynes
FSFan Shuangyi
Fan Shuangyi
YPYanfen Peng
Yanfen Peng
SSShruti Sridhar
Shruti Sridhar
AJAnand D. Jeyasekharan
Anand D. Jeyasekharan
Evaluation of M+2+6− cells in scRNA-seq datasets of DLBCL. A, Uniform Manifold Approximation and Projection (UMAP) of malignant B cells from the Roider and Steen cohorts. B, Proportion of subpopulations across samples and annotation of M+2+6− cells in UMAP. C, Correlation of genes enriched in the M+2+6− subpopulation as evaluated by scRNA-seq with hits from the bulk GEP cohorts (Fig. 5E). CCND2 is highlighted and is among the concordant hits (see also Supplementary Table S13). D, WikiPathways terms enrichment among genes positively associated with M+2+6− cells. Both axes in C and D are scaled exponentially for clarity (see also Supplementary Table S14).